Which super funds hold Teva Pharmaceutical Finance Netherlands II BV?

As at 31 December 2025, 10 Australian super investment options in our dataset held Teva Pharmaceutical Finance Netherlands II BV, the largest weighting being 0.01% in Diversified Fixed Interest (Accumulation) (AustralianSuper).

Options holding it

10

Largest weighting

0.01%

Diversified Fixed Interest (Accumulation) · AustralianSuper

Funds & options holding Teva Pharmaceutical Finance Netherlands II BV

Australian super investment options disclosing a holding in Teva Pharmaceutical Finance Netherlands II BV. Figures aggregate each option's disclosed line items for this security, as at each option's own reporting date.

FundPhaseOptionWeightingValue (AUD)As at
AustralianSuperAccumulationBalanced (Accumulation)
0.00%
$2,651,58031 December 2025
AustralianSuperRetirementBalanced (Income)
0.00%
$351,87031 December 2025
AustralianSuperRetirementConservative Balanced (Income)
0.00%
$163,87331 December 2025
AustralianSuperAccumulationStable (Accumulation)
0.00%
$143,56431 December 2025
AustralianSuperAccumulationConservative Balanced (Accumulation)
0.00%
$135,76231 December 2025
AustralianSuperRetirementStable (Income)
0.00%
$132,07031 December 2025
AustralianSuperAccumulationDiversified Fixed Interest (Accumulation)
0.01%
$109,72831 December 2025
AustralianSuperAccumulationHigh Growth (Accumulation)
0.00%
$87,00731 December 2025
AustralianSuperRetirementDiversified Fixed Interest (Income)
0.01%
$51,90231 December 2025
AustralianSuperRetirementHigh Growth (Income)
0.00%
$5,83731 December 2025

This page surfaces figures disclosed by the funds themselves under Portfolio Holdings Disclosure (Schedule 8D), each as at the date shown. It is factual disclosure information, not financial advice or a recommendation.

Methodology — how holdings are sourced, resolved and aggregated.

LookThrough shows the actual holdings inside Australian super funds, with cross-fund look-through.

  • 4 of 86 funds
  • 111 of 111 options reviewed
  • 7,010 of 7,168 securities reviewed

© 2026 LookThrough. Factual disclosure information — not financial advice, a rating or a recommendation.